A high endothelial venule secretory protein, mac25/angiomodulin, interacts with multiple high endothelial venule-associated molecules including chemokines.
We previously reported that mac25/angiomodulin (AGM), a 30-kDa secretory protein, is abundantly expressed in high endothelial venules (HEVs), which play a crucial role in lymphocyte trafficking to the lymph nodes and Peyer's patches. We report that mac25/AGM interacts preferentially with certain molecules that are expressed in or around HEVs. In particular, mac25/AGM interacted with not only the extracellular matrix proteins and glycosaminoglycans that are expressed in most blood vessels including HEVs, but also with some chemokines that are implicated in the regulation of lymphocyte trafficking, such as the secondary lymphoid-tissue chemokine (SLC; CCL21), IFN-gamma-inducible protein 10 (IP-10; CXCL10), and RANTES (CCL5). The binding of mac25/AGM to SLC and IP-10 was dose-dependent and saturable. The binding to IP-10 could be inhibited by SLC but not by a non-mac25/AGM-binding chemokine, EBI1-ligand chemokine (ELC; CCL19). Interestingly, mac25/AGM failed to interact with 18 other chemokines, suggesting that it binds to certain chemokines preferentially. Immunohistochemical analysis indicated that mac25/AGM colocalizes at least partially with SLC and IP-10 at the basal lamina of HEVs. Upon binding with mac25/AGM, SLC and IP-10 retained all their Ca(2+)-signaling activity in vitro, suggesting that mac25/AGM can hold and present chemokines in the basal lamina of HEVs. These results imply that mac25/AGM plays a multifunctional role, serving not only as an adhesion protein to interact with glycosaminoglycans and extracellular matrix proteins but also as a molecule to present chemokines so that lymphocytes extravasating through HEVs receive further directional cues subsequent to the luminal encounter with lymphoid chemokines.
Nagakubo
Daisuke
D
Laboratory of Molecular and Cellular Recognition, Osaka University Graduate School of Medicine, Suita, Japan.
Murai
Toshiyuki
T
Tanaka
Toshiyuki
T
Usui
Takeo
T
Matsumoto
Masanori
M
Sekiguchi
Kiyotoshi
K
Miyasaka
Masayuki
M
D000595:Amino Acid Sequence; D000818:Animals; D001665:Binding Sites / Q000276:immunology; D020013:Calcium Signaling / Q000276:immunology; D002352:Carrier Proteins / Q000378:metabolism* / Q000502:physiology; D002460:Cell Line; D054421:Chemokine CCL21; D054357:Chemokine CXCL10; D018925:Chemokines / Q000378:metabolism* / Q000502:physiology; D019742:Chemokines, CC / Q000378:metabolism; D019743:Chemokines, CXC / Q000378:metabolism; D002634:Chemotaxis, Leukocyte / Q000276:immunology; D004729:Endothelium, Lymphatic / Q000098:blood supply / Q000378:metabolism* / Q000502:physiology; D016326:Extracellular Matrix Proteins / Q000096:biosynthesis / Q000378:metabolism; D005260:Female; D006025:Glycosaminoglycans / Q000096:biosynthesis / Q000378:metabolism; D018969:Insulin-Like Growth Factor Binding Proteins; D051379:Mice; D008810:Mice, Inbred C57BL; D008969:Molecular Sequence Data; D009363:Neoplasm Proteins / Q000378:metabolism* / Q000502:physiology; D011485:Protein Binding / Q000276:immunology; D014699:Venules / Q000378:metabolism* / Q000502:physiology
D002352:Carrier Proteins; C515479:Ccl21c protein, mouse; D054421:Chemokine CCL21; D054357:Chemokine CXCL10; D018925:Chemokines; D019742:Chemokines, CC; D019743:Chemokines, CXC; D016326:Extracellular Matrix Proteins; D006025:Glycosaminoglycans; D018969:Insulin-Like Growth Factor Binding Proteins; D009363:Neoplasm Proteins; C102529:insulin-like growth factor binding protein-related protein 1; C086009:tumor-derived adhesion factor